ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention.

[1]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[2]  David B Matchar,et al.  Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.

[3]  R. Morishita,et al.  Stent-Based Local Delivery of Nuclear Factor-&kgr;B Decoy Attenuates In-Stent Restenosis in Hypercholesterolemic Rabbits , 2006, Circulation.

[4]  M. West,et al.  Molecular evidence for arterial repair in atherosclerosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  E. Eisenstein,et al.  Decision models for assessing the cost effectiveness of drug-eluting stents , 2005, Expert opinion on pharmacotherapy.

[6]  M. West,et al.  Gene Expression Phenotypes of Atherosclerosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[7]  J. Gulcher,et al.  The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke , 2004, Nature Genetics.

[8]  Charles L. Brown,et al.  Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis , 2004, Circulation.

[9]  Mary E. Russell,et al.  TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.

[10]  E. Hawe,et al.  The endothelial nitric oxide synthase (Glu298Asp and –786T>C) gene polymorphisms are associated with coronary in-stent restenosis , 2002 .

[11]  A. Zwinderman,et al.  A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias. , 2002, American heart journal.

[12]  B. Davis,et al.  Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial , 2002, Circulation.

[13]  S. Anker,et al.  The E-selectin SER128ARG gene polymorphism and restenosis after successful coronary angioplasty. , 2002, International journal of cardiology.

[14]  P. Amouyel,et al.  The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. , 2002, European heart journal.

[15]  Levon M Khachigian,et al.  Coronary In-stent Restenosis: Current Status and Future Strategies , 2022 .

[16]  A. Kastrati,et al.  Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. , 2001, The American journal of cardiology.

[17]  L. Marshall,et al.  Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis. , 2000, The Journal of pharmacology and experimental therapeutics.

[18]  G. Yancopoulos,et al.  Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development , 2000, Nature Genetics.

[19]  M. Hadamitzky,et al.  Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.

[20]  K. Miyazawa,et al.  Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. , 1996, Japanese journal of pharmacology.

[21]  R H Jones,et al.  Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery. , 1991, Circulation.

[22]  Vilmundur Gudnason,et al.  A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.

[23]  E. Hawe,et al.  The endothelial nitric oxide synthase ( Glu 298 Asp and – 786 T > C ) gene polymorphisms are associated with coronary in-stent restenosis , 2002 .

[24]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[25]  M. Nakazawa,et al.  Mechanism of inhibitory action of tranilast on the release of slow reacting substance of anaphylaxis (SRS-A) in vitro: effect of tranilast on the release of arachidonic acid and its metabolites. , 1988, Japanese journal of pharmacology.